10月31日，昭衍新药涨5.12%，截至发稿，报37.18元/股，成交9.99亿元，换手率4.41%，总市值278.66 亿元。 资料显示，北京昭衍新药研究中心股份有限公司位于北京市经济技术开发区荣京东街甲5号,香港铜锣湾 希慎道33号利园1期19楼1920室，成立日期1998年2月25日，上市日期2017年8月25日，公司主营业务涉 及以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。主营业 务收入构成为：药物非临床研究服务95.59%，临床服务4.34%，实验模型供应0.07%。 融通医疗保健行业混合A/B（161616）基金经理为万民远、刘曦阳。 截至发稿，万民远累计任职时间9年69天，现任基金资产总规模59.57亿元，任职期间最佳基金回报 144.04%， 任职期间最差基金回报-20.09%。 刘曦阳累计任职时间1年231天，现任基金资产总规模8.39亿元，任职期间最佳基金回报-1.31%， 任职期 间最差基金回报-2.08%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的 ...

Core Insights - Huaxia Eye Hospital (301267.SZ) released its Q3 2025 report, indicating that as of October 28, 2025, 11 institutional investors held a total of 442 million shares, representing 52.60% of the total share capital [1] - The top ten institutional investors collectively held 52.06% of the shares, with a slight decrease of 0.14 percentage points compared to the previous quarter [1] Institutional Holdings - The top ten institutional investors include Huaxia Medical Investment (Xiamen) Co., Ltd., Xiamen Hanwei Equity Investment Partnership (Limited Partnership), and several other Xiamen-based investment firms [1] - One public fund, Huabao Zhongzheng Medical ETF, reported a decrease in holdings by 0.14% compared to the previous quarter [1] - A total of 180 public funds did not disclose their holdings this quarter, including notable funds such as E Fund ChiNext ETF and Southern CSI 500 ETF [1]

8月28日，昭衍新药跌5.53%，截至发稿，报30.21元/股，成交4.08亿元，换手率2.08%，总市值226.42亿 元。 资料显示，北京昭衍新药研究中心股份有限公司位于北京市经济技术开发区荣京东街甲5号,香港铜锣湾 希慎道33号利园1期19楼1920室，成立日期1998年2月25日，上市日期2017年8月25日，公司主营业务涉 及以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。 从基金十大重仓股角度 融通医疗保健行业混合A/B（161616）基金经理为万民远、刘曦阳。 截至发稿，万民远累计任职时间9年5天，现任基金资产总规模42.23亿元，任职期间最佳基金回报 156.05%， 任职期间最差基金回报-17.58%。 刘曦阳累计任职时间1年167天，现任基金资产总规模8.14亿元，任职期间最佳基金回报1.41%， 任职期 间最差基金回报0.98%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，融通基金 ...

Core Viewpoint - The AI Fund for Health Industry Flexible Allocation Mixed A/B (000727) reported a profit of 179 million yuan in Q2 2025, with a net asset value growth rate of 8.97% for the period [2] Fund Performance - As of July 17, the fund's unit net value was 2.661 yuan, with a recent three-month growth rate of 15.00%, ranking 108 out of 138 comparable funds [3] - The fund's six-month growth rate was 16.45%, ranking 117 out of 138, and the one-year growth rate was 19.86%, ranking 107 out of 133 [3] - Over the past three years, the fund's growth rate was -9.89%, ranking 64 out of 106 [3] Risk and Return Metrics - The fund's Sharpe ratio over the past three years was 0.1159, ranking 48 out of 105 comparable funds [8] - The maximum drawdown over the past three years was 45.79%, with the highest quarterly drawdown occurring in Q1 2024 at 26.05% [11] Investment Strategy - The fund focuses on selecting sectors and stocks with good growth potential and relatively low valuations, aligning with the structural upgrades in China's pharmaceutical industry and the recovery of medical demand [2] - Key investment areas include innovation-driven industry upgrades, import substitution, and recovery in hospital medical services, with a focus on innovative drugs, medical devices, and low price-to-book (PB) assets [2] Fund Composition - As of June 30, the fund maintained an average stock position of 92.67% over the past three years, with a peak of 94.13% at the end of Q1 2024 [14] - The fund's total assets reached 2.074 billion yuan as of the end of Q2 2025 [15] - The top ten holdings include Yixin Hall, Aibo Medical, Sanyou Medical, Jianzhijia, Kaili Medical, Sunshine Nuohuo, Dongfang Biological, Puri Eye Hospital, Meihao Medical, and Meinian Health [18]